Patent: 8,524,217
✉ Email this page to a colleague
Summary for Patent: 8,524,217
Title: | MCP1-Ig fusion variants |
Abstract: | The present invention provides, in part, MCP1-Ig fusion polypeptides exhibiting surprisingly beneficial properties as well as methods for treating various diseases (e.g., inflammatory diseases) by administering any of such fusions. |
Inventor(s): | Presta; Leonard G. (San Francisco, CA), Chou; Chuan-Chu (Westfield, NJ) |
Assignee: | Merck Sharp & Dohme Corp. (Rahway, NJ) |
Application Number: | 13/105,453 |
Patent Claims: | see list of patent claims |
Details for Patent 8,524,217
Applicant | Tradename | Biologic Ingredient | Dosage Form | BLA | Approval Date | Patent No. | Expiredate |
---|---|---|---|---|---|---|---|
Genentech, Inc. | RITUXAN | rituximab | Injection | 103705 | 11/26/1997 | ⤷ Try a Trial | 2030-05-11 |
Idec Pharmaceuticals Corp. | RITUXAN | rituximab | Injection | 103737 | 02/19/2002 | ⤷ Try a Trial | 2030-05-11 |
Janssen Biotech, Inc. | REMICADE | infliximab | For Injection | 103772 | 08/24/1998 | ⤷ Try a Trial | 2030-05-11 |
Immunex Corporation | ENBREL | etanercept | For Injection | 103795 | 11/02/1998 | ⤷ Try a Trial | 2030-05-11 |
Immunex Corporation | ENBREL | etanercept | For Injection | 103795 | 05/27/1999 | ⤷ Try a Trial | 2030-05-11 |
>Applicant | >Tradename | >Biologic Ingredient | >Dosage Form | >BLA | >Approval Date | >Patent No. | >Expiredate |